Ventyx biosciences announces presentation of data from the phase 2 trial of allosteric tyk2 inhibitor vtx958 in crohn's disease at ecco 2025

Poster highlights robust, dose-dependent endoscopic response with vtx958 and reductions in key inflammatory markers full analysis of phase 2 results, including data from the 52-week treat-through lte phase, is expected to inform development strategy and partnership opportunities for vtx958 san diego, feb. 18, 2025 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”, “company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the phase 2 trial of its tyk2 inhibitor vtx958 in crohn's disease will be presented during the 20th congress of the european crohn's and colitis organisation (ecco) being held in berlin, germany from february 19-22, 2025. “the phase 2 data for vtx958 in crohn's disease represent an important milestone for tyk2 inhibition in inflammatory bowel disease,” said raju mohan, phd, founder and chief executive officer.
VTYX Ratings Summary
VTYX Quant Ranking